Furthermore, Ruxolitinib, a JAK1/2 inhibitor, was able to overcome chemoresistance and to improve survival in the immunocompetent OC mouse model system using ID8 tumor cells and MSCs, alongside a decrease in pSTAT3 levels [54]. The gene discussed is JAK1; the disease is neoplasm.